DiaMedica Therapeutics Inc. (DMAC)
NASDAQ: DMACHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Oct 8, 4:00 PM ET · Delayed 15 min
DMAC stock chart
Technical analysisKey statistics
All statistics- Market cap
- $431.94M
- EPS (TTM)
- -$0.72
- Dividend yield
- None
- 52-week range
- 5.25 – 10.42
- Day range
- 7.66 – 8.06
- Volume / Avg
- 237.88K / 177.22K
- Beta
- —
- Shares outstanding
- 53.93M
52-week range
DMAC stock today
Shares of DiaMedica Therapeutics (DMAC) finished higher on Oct 8 at $8.01, a gain of 0.25% or $0.02 per share, versus the S&P 500's 0.47% decline. Shares are 23.1% below their 52-week high of $10.42, set on Dec 10, 2025 and 52.7% above the 52-week low of $5.25, in the middle of the past year's range. DMAC is up 0.6% year to date, underperforming the S&P 500 (+13.5%). Over the past 12 months, the stock has gained 15.1%.
DiaMedica Therapeutics has posted a net loss over the last twelve months (EPS of -$0.72), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About DiaMedica Therapeutics
Company profileDiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from severe ischemic diseases. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase 2/3 trials for the treatment of acute ischemic stroke, as well as in Phase 2 to treat preeclampsia, cardio renal disease, and fetal growth restriction. The company develops DM300, which is a recombinant human ulinastatin in the preclinical stage for the treatment of inflammatory diseases, such as acute pancreatitis.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Mr. Dietrich John Pauls MBA
- Headquarters
- Minneapolis, MN
- Employees
- 35
- IPO year
- 2018
- Website
- diamedica.com
Analyst forecast
ForecastConsensus (5 analysts)
strong_buy
Avg. price target
$15.50+93.51%
- Strong buy 0
- Buy 5
- Hold 0
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
DiaMedica Therapeutics peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| PRTAProthena Corporation plc | 8.61 | +1.53% | $442.01M | vs DMAC |
| AVIRAtea Pharmaceuticals Inc. | 5.16 | +2.89% | $413.46M | vs DMAC |
| KMDAKamada Ltd. | 7.78 | -1.46% | $448.70M | vs DMAC |
| RZLTRezolute Inc. | 4.64 | +5.94% | $448.79M | vs DMAC |
| SPRYARS Pharmaceuticals Inc. | 4.56 | +4.59% | $453.48M | vs DMAC |
| OVIDOvid Therapeutics Inc. | 2.34 | -0.85% | $457.00M | vs DMAC |
| ASMBAssembly Biosciences Inc. | 22.82 | -0.57% | $464.63M | vs DMAC |
| CAPRCapricor Therapeutics Inc. | 8.01 | -1.11% | $465.69M | vs DMAC |
Indexes, lists and sector
DiaMedica Therapeutics stock FAQ
What is DiaMedica Therapeutics's stock price today?
DMAC last traded at $8.01 as of Oct 8, 4:00 PM EDT, up 0.25% on the day. Prices are delayed at least 15 minutes.
Does DiaMedica Therapeutics pay a dividend?
No. DiaMedica Therapeutics does not currently pay a regular cash dividend.
Who is DiaMedica Therapeutics's CEO?
Mr. Dietrich John Pauls MBA is the chief executive officer of DiaMedica Therapeutics Inc., which has about 35 employees.
Has DMAC ever split its stock?
Yes. The most recent DMAC stock split was a 1-for-20 split on Nov 15, 2018.
What is the DMAC 52-week high?
The 52-week high for DMAC is $10.42 and the 52-week low is $5.25. The stock is currently 23.1% below its high.